KR20230002706A - 결정질 ret 억제제 - Google Patents

결정질 ret 억제제 Download PDF

Info

Publication number
KR20230002706A
KR20230002706A KR1020227039684A KR20227039684A KR20230002706A KR 20230002706 A KR20230002706 A KR 20230002706A KR 1020227039684 A KR1020227039684 A KR 1020227039684A KR 20227039684 A KR20227039684 A KR 20227039684A KR 20230002706 A KR20230002706 A KR 20230002706A
Authority
KR
South Korea
Prior art keywords
selpercatinib
acid
slurry
water
cancer
Prior art date
Application number
KR1020227039684A
Other languages
English (en)
Korean (ko)
Inventor
라즈니 미글라니 바드와즈
마크 스티븐 커
더글라스 패튼 키엘
제레미 마일스 메리트
존 고든 셀보
셰카 크리쉬나 비스와나스
Original Assignee
록쏘 온콜로지, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 록쏘 온콜로지, 인코포레이티드 filed Critical 록쏘 온콜로지, 인코포레이티드
Publication of KR20230002706A publication Critical patent/KR20230002706A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Semiconductor Lasers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020227039684A 2020-04-17 2021-04-09 결정질 ret 억제제 KR20230002706A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063011701P 2020-04-17 2020-04-17
US63/011,701 2020-04-17
US202163151354P 2021-02-19 2021-02-19
US63/151,354 2021-02-19
PCT/US2021/026611 WO2021211380A1 (en) 2020-04-17 2021-04-09 Crystalline ret inhibitor

Publications (1)

Publication Number Publication Date
KR20230002706A true KR20230002706A (ko) 2023-01-05

Family

ID=75747118

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039684A KR20230002706A (ko) 2020-04-17 2021-04-09 결정질 ret 억제제

Country Status (17)

Country Link
EP (1) EP4136090A1 (es)
JP (1) JP2023522012A (es)
KR (1) KR20230002706A (es)
CN (1) CN115916791A (es)
AU (1) AU2021255488B2 (es)
BR (1) BR112022020446A2 (es)
CA (1) CA3174316A1 (es)
CL (1) CL2022002849A1 (es)
CO (1) CO2022014882A2 (es)
CR (1) CR20220520A (es)
DO (1) DOP2022000221A (es)
EC (1) ECSP22080982A (es)
IL (1) IL297212A (es)
MX (1) MX2022012952A (es)
PE (1) PE20230388A1 (es)
TW (1) TW202202501A (es)
WO (1) WO2021211380A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022069357A1 (en) * 2020-10-01 2022-04-07 Sandoz Ag Crystalline form of selpercatinib
MX2024007017A (es) 2021-12-13 2024-06-19 Loxo Oncology Inc Procesos para la preparacion de la forma cristalina a de selpercatinib. un inhibidor ret.
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704148B (zh) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TW202410896A (zh) * 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI783057B (zh) * 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
EP3845531A4 (en) * 2018-09-30 2021-11-24 Applied Pharmaceutical Science, Inc. SUBSTITUTED PYRAZOLE-CONDENSED RING DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE THEREOF
CN111004257B (zh) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 制备RET抑制剂Selpercatinib的方法

Also Published As

Publication number Publication date
DOP2022000221A (es) 2023-01-15
CO2022014882A2 (es) 2022-10-31
EP4136090A1 (en) 2023-02-22
WO2021211380A1 (en) 2021-10-21
ECSP22080982A (es) 2023-01-31
TW202202501A (zh) 2022-01-16
CR20220520A (es) 2022-11-15
MX2022012952A (es) 2023-01-11
AU2021255488B2 (en) 2024-05-30
CN115916791A (zh) 2023-04-04
CL2022002849A1 (es) 2023-06-16
JP2023522012A (ja) 2023-05-26
AU2021255488A1 (en) 2022-11-10
PE20230388A1 (es) 2023-03-06
IL297212A (en) 2022-12-01
BR112022020446A2 (pt) 2022-11-29
CA3174316A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
AU2021255488B2 (en) Crystalline RET inhibitor
CN113717157B (zh) 用作cdk7激酶抑制剂的化合物及其应用
CN118139855A (zh) 1,4-氧杂氮杂环庚烷衍生物及其用途
TWI698428B (zh) Mdm2抑制劑之製備方法及結晶型
KR102090453B1 (ko) 상피 성장 인자 수용체 키나제 억제제의 염
CN111362967B (zh) 苯并氧杂二氮杂十四碳烯衍生物及其用途
RU2633694C2 (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
CN111961034A (zh) 用作ret激酶抑制剂的化合物及其应用
WO2020011254A1 (zh) 作为pde3/pde4双重抑制剂的三并环类化合物
CA3200620A1 (en) Aromatic heterocyclic compound, and pharmaceutical composition and application thereof
TW201629060A (zh) 一種週期素依賴性蛋白激酶抑制劑的羥乙基磺酸鹽、其結晶形式及製備方法
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
US20230212193A1 (en) Crystalline ret inhibitor
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
KR20240042619A (ko) 유기 피리딘-피라졸 화합물 및 이의 용도
WO2022033563A1 (zh) Jak抑制剂化合物及其用途
CN117729921A (zh) 作为pd1/pd-l1抑制剂的化合物及其方法
US20230183266A1 (en) Crystalline forms of ret inhibitor and preparation thereof
WO2024104354A1 (zh) 一种取代的哌嗪衍生物的晶体及其制备方法
US20240317746A1 (en) Crystalline forms of an azetidine parp1 inhibitor
TW202438067A (zh) 吖呾ｐａｒｐ１抑制劑之晶形
WO2023134608A1 (zh) 作为hpk1抑制剂的稠环化合物
TW202333672A (zh) Ｒｏｃｋ抑制劑的鹽及鹽的晶型、組合物和藥物用途
TW202430184A (zh) Kras g12d抑制劑的結晶形式及製備方法

Legal Events

Date Code Title Description
A201 Request for examination